Editorial introductions : Current Opinion in Cardiology

Secondary Logo

Journal Logo


Editorial introductions

Editor(s): Roberts, Robert; Su, Wilber W.; Mortensen, Martin Bødtker

Current Opinion in Cardiology 38(1):p v-vi, January 2023. | DOI: 10.1097/HCO.0000000000001008
  • Free

Current Opinion in Cardiology was launched in 1985. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of cardiology is divided into 14 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Editor and Section Editors for this issue.


Robert Roberts

Robert Roberts

Dr Roberts is an Executive Director of the Heart and Vascular Institute for Dignity Health at St Joseph’ Hospital and Medical Center in Phoenix, Arizona, USA. He is Professor of Medicine at the University of Arizona School of Medicine Phoenix and holds the Chair in ISCTR. He was the President and CEO of the University of Ottawa Heart Institute, Canada, (2004–2014) and the Founder and Director of The Ruddy Canadian Cardiovascular Genetics Centre, Canada. He received his M.D. from Dalhousie University, Canada, and completed his residency in internal medicine and fellowship in cardiology at the University of Toronto, Canada. Funded by a Canadian Heart Foundation Scholarship, he pursued research in heart disease at the University of California, USA, followed by a faculty position at Washington University and Director of the CCU at Barnes Hospital, St Louis, USA. In 1982 he became Chief of Cardiology at Baylor College of Medicine in Houston, Texas, USA.

Dr Roberts developed the MBCK Test, the standard used to diagnose heart attacks for three decades. Dr Roberts’ research led him to molecular biology and genetics, during which time he discovered many genes responsible for single gene disorders of the heart including FHCM, FDCM, atrial fibrillation, WPW and ARVG. In the past 10 years, he has pursued a major effort, which resulted in discovery of 9p21, the first genetic risk variant for CAD. In collaboration with an international consortium he has been involved with the discovery of over 100 genetic risk variants for CAD.

Dr Roberts is generally regarded as one of the founders of molecular cardiology. He has been the Associate Editor of Hurst's the Heart for more than two decades and co-authored the section on Cardiovascular Genetics. He is Senior Guest Editor for JACC: Basic Translational Science and Section Editor for Genomics and Genetics for the parent journal, JACC. He is Associate Editor of Trends in Cardiovascular Medicine, authors Gene of the Month for Cardiology Today and is on the Editorial Board for multiple other cardiovascular journals.

Dr Roberts has had a distinguished and prolific career as a Cardiologist, Educator and Scientist having published over 960 scientific articles. In recognition of his scientific contributions he was elected a Fellow of Academy of Science of the Royal Society of Canada in 2013, received the Distinguished Scientist Award of the American College of Cardiology in 1998 and the Award of Meritorious Achievement from the American Heart Association in 2001. He has received many other awards including the 2012 Research Achievement Award from the Canadian Cardiovascular Society; the 2012 Distinguished Fellowship Award from the International Academy of Cardiology; the McLaughlin Medal from the Royal Society of Canada; the Albrecht Fleckenstein Memorial Award from the International Academy of Cardiology in 2008; Citation for Highly Cited Researcher from ISI Thomson Scientific in 2002.

Wilber W. Su

Wilber W. Su

Dr Wilber W. Su is the Director of Cardiac Electrophysiology Banner-University Medical Center and Associate Professor of Medicine at the University of Arizona, USA, as well as Stanford University Medical Center, USA. He has a biomedical engineering degree from Massachusetts Institute of Technology, and received his training at Mayo Clinic Rochester, Minnesota, USA, for medicine, cardiology, clinician investigator fellowship and cardiac electrophysiology.

He has been a high-volume operator and has served as a training physician in both implantable cardiac devices and complex ablation, notably in atrial fibrillation. He is also active in research with multiple important clinical trials and is the national primary investigator for several research trials. He is recognized as a key opinion and thought leader around the world in cryoballoon ablation and has personally performed over 3000 cryoballoon ablation procedures for atrial fibrillation, the highest volume world-wide. He has also taught, presented, and published on various cryoballoon techniques. His latest publication highlights his leadership in the field of cryoballoon ablation, and is titled “Best Practice Guide for Cryoballoon Ablation in Atrial Fibrillation: The compilation experience of over 3000 Procedures” as well as “Best Practice Guide II-Focus on Dosing” and book chapters on Cryoballoon Ablation. He is also a member of the writing committee for the American Heart Association and Heart Rhythm Society national guidelines.

Martin Bødtker Mortensen

Martin Bødtker Mortensen

Martin Bødtker Mortensen MD PhD is Associate Professor at the Department of Cardiology at Aarhus University Hospital, Denmark, and Adjunct Associate Professor at the Ciccarone Center for The Prevention of Cardiovascular Disease, Johns Hopkins, Baltimore, USA.

Dr Mortensen graduated from the medical school at Aarhus University in 2011 and have since then worked extensively with atherosclerotic cardiovascular disease both clinically and in his research. He obtained his PhD degree in 2015, based on experimental work performed in Dr Jacob Bentzons and Professor Erling Falks laboratory at the Department of Cardiology, Aarhus University Hospital, Denmark. Dr Mortensen's research field covers both experimental research on the pathogenesis of atherosclerosis as well as epidemiological and clinical studies into the risk and prevention of atherosclerotic cardiovascular disease in humans. Particularly, he has worked extensively on the utility of using non-invasive imaging of subclinical atherosclerosis to identify individuals at low or high risk for development of future clinical disease. Dr Mortensen have published over 100 scientific articles, including in high-impact journals such as Lancet, BMJ, JACC, EHJ, Circulation, JAMA Cardiology and JCI. He is internationally recognized within the field and has received both national and international awards for his research. He has authored several book chapters regarding atherosclerosis, atherosclerotic cardiovascular disease, and dyslipidemias.

Dr Mortensen treats patients with lipid disorders, including rare genetic dyslipidemias and familial hypercholesterolemia, in the advanced lipid-clinic at Aarhus University Hospital. Dr Mortensen serves as the chairman for the Preventive Cardiology group in Denmark (under the Danish Society of Cardiology). He has for many years participated in writing the Danish guidelines for treatment of dyslipidemia and prevention of cardiovascular disease issued by the Danish Society of Cardiology and is a regular speaker for the Danish Heart Foundation on the role of cholesterol in the development of atherosclerosis.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.